IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases. The company's lead product candidate, batoclimab, is a fully human monoclonal antibody that inhibits the neonatal Fc receptor (FcRn), which plays a key role in regulating IgG antibody levels. Immunovant is advancing batoclimab through clinical trials for multiple autoimmune indications, including myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia. The company's approach aims to reduce pathogenic antibodies that drive autoimmune disease progression while maintaining overall immune function.